Business Description
Virax Biolabs Group Ltd
ISIN : KYG9495L1251
Share Class Description:
VRAX: Class ATotal Employee Number:
19Description
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.22 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -6.17 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -0.4 | |||||
3-Year EPS without NRI Growth Rate | -2.5 | |||||
3-Year FCF Growth Rate | -24.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.8 | |||||
9-Day RSI | 37.02 | |||||
14-Day RSI | 39.5 | |||||
3-1 Month Momentum % | 39.07 | |||||
6-1 Month Momentum % | -49.56 | |||||
12-1 Month Momentum % | -75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.37 | |||||
Quick Ratio | 11.22 | |||||
Cash Ratio | 9.16 | |||||
Days Inventory | 680.34 | |||||
Days Sales Outstanding | 182.5 | |||||
Days Payable | 538.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -57 | |||||
Shareholder Yield % | -89.27 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -1533.33 | |||||
Operating Margin % | -195633.33 | |||||
Net Margin % | -188133.33 | |||||
EBITDA Margin % | -182066.67 | |||||
FCF Margin % | -196766.67 | |||||
OCF Margin % | -180166.67 | |||||
ROE % | -86.15 | |||||
ROA % | -78.44 | |||||
ROIC % | -298.07 | |||||
ROC (Joel Greenblatt) % | -341.06 | |||||
ROCE % | -88.61 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 192.2 | |||||
PB Ratio | 0.15 | |||||
Price-to-Tangible-Book | 0.15 | |||||
EV-to-EBIT | 0.1 | |||||
EV-to-Forward-EBIT | 0.01 | |||||
EV-to-EBITDA | 0.11 | |||||
EV-to-Revenue | -198.33 | |||||
EV-to-Forward-Revenue | 1.29 | |||||
EV-to-FCF | 0.1 | |||||
Price-to-GF-Value | 2.69 | |||||
| Price-to-Net-Current-Asset-Value | 0.22 | |||||
| Price-to-Net-Cash | 0.27 | |||||
Earnings Yield (Greenblatt) % | 1000 | |||||
FCF Yield % | -240.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VRAX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Virax Biolabs Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.003 | ||
| EPS (TTM) ($) | -30.5 | ||
| Beta | 1.5153 | ||
| 3-Year Sharpe Ratio | -0.14 | ||
| 3-Year Sortino Ratio | -0.35 | ||
| Volatility % | 75.5 | ||
| 14-Day RSI | 39.5 | ||
| 14-Day ATR ($) | 0.743778 | ||
| 20-Day SMA ($) | 3.925625 | ||
| 12-1 Month Momentum % | -75 | ||
| 52-Week Range ($) | 2.5 - 28.5 | ||
| Shares Outstanding (Mil) | 0.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Virax Biolabs Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Virax Biolabs Group Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2026-11-30 | In 146 days | ||
| First quarter earnings results for 2027 | 2026-08-31 | In 55 days | ||
| Annual report for 2026 | 2026-07-09 | In 2 days | ||
| 0.04:1 Stock Split | 2026-06-26 | 3.38 (+0.00%) | ||
| General meeting for 2025 | 2026-03-18 13:00 | 5.07 (+4.70%) | ||
| Annual report for 2024 | 2025-08-20 | 19.38 (+0.34%) | ||
| Annual report for 2025 | 2025-07-02 | 21.00 (+6.82%) | ||
| General meeting for 2024 | 2024-12-12 13:00 | 42.50 (-3.41%) | ||
| 0.1:1 Stock Split | 2023-12-18 | 39.70 (-6.53%) |
Show
Entries
Virax Biolabs Group Ltd Frequently Asked Questions
What is Virax Biolabs Group Ltd(VRAX)'s stock price today?
The current price of VRAX is $3.09. The 52 week high of VRAX is $28.50 and 52 week low is $2.50.
When is next earnings date of Virax Biolabs Group Ltd(VRAX)?
The next earnings date of Virax Biolabs Group Ltd(VRAX) is 2026-08-31 Est..
Does Virax Biolabs Group Ltd(VRAX) pay dividends? If so, how much?
Virax Biolabs Group Ltd(VRAX) does not pay dividend.
Guru Commentaries on NAS:VRAX
No articles.
Press Release
Articles on Virax Biolabs Group Ltd
No articles.
Headlines
See More- 1
Jun 24, 2026
Virax Biolabs Group announces 1-for-25 share consolidation
Seeking Alpha • 9:00am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers